Framingham Risk Score

Estimate 10-year cardiovascular risk based on the Framingham Heart Study equations.

Last updated on: July 7, 2025

Enter Patient Data

years
mmHg

What is the Framingham Risk Score?

The Framingham Risk Score is a gender-specific algorithm developed from the Framingham Heart Study to estimate the 10-year cardiovascular risk of an individual. It considers age, cholesterol levels, blood pressure, smoking, and diabetes status.

Why is this Score Useful?

It is widely used in clinical practice to guide decisions on preventive therapies such as statins, lifestyle changes, and blood pressure control. The score helps clinicians and patients quantify risk and take proactive measures to prevent heart disease.

How to Interpret the Result

The calculated percentage represents the estimated chance of developing cardiovascular disease within the next 10 years. Risk is classified into four categories: low, borderline, intermediate, or high.

Practical Recommendations

  • Maintain a healthy lifestyle with regular exercise and a balanced diet.
  • Achieve and sustain optimal blood pressure levels.
  • Quit smoking to drastically lower cardiovascular risk.
  • Control cholesterol and lipid levels with diet or medication as prescribed.
  • Screen and manage diabetes appropriately.
  • Schedule regular medical check-ups for early detection and prevention.

Risk Stratification

Low Risk: Your 10-year cardiovascular risk is <5%. Focus on lifestyle optimization: healthy diet, physical activity, weight management, and no smoking.
Borderline Risk: Your 10-year risk is 5–7.5%. Lifestyle modification is recommended. Discuss additional preventive options (e.g., statins) with your physician if other risk factors are present.
Intermediate Risk: Your 10-year risk is 7.5–20%. Preventive pharmacological therapy (e.g., statins) is usually recommended, in addition to intensive lifestyle changes.
High Risk: Your 10-year risk is >20%. Strong recommendations for pharmacological therapy (statins, antihypertensives) plus aggressive risk factor control.

This page has been medically reviewed by Dr. Khoulah Attia – PharmD, Immunology Specialist.